The drug being tested in this study is called Brigatinib (AP26113). Brigatinib is being tested to treat people with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This study will look at the efficacy of Brigatinib.